{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T23:44:09Z","timestamp":1792453449741,"version":"4.5.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,4]],"date-time":"2025-01-04T00:00:00Z","timestamp":1735948800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,1,4]],"date-time":"2025-01-04T00:00:00Z","timestamp":1735948800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Merck Serono Middle East"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1007\/s40120-024-00707-5","type":"journal-article","created":{"date-parts":[[2025,1,4]],"date-time":"2025-01-04T22:16:19Z","timestamp":1736028979000},"page":"413-427","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Administration and Monitoring Burden of High-Efficacy Disease-Modifying Therapies for Multiple Sclerosis: A Delphi Consensus of Clinical Experts from Saudi Arabia"],"prefix":"10.1007","volume":"14","author":[{"given":"Seraj","family":"Makkawi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad","family":"Abulaban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaser","family":"Al Malik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ebtesam","family":"Alshehri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Althobaiti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0138-7924","authenticated-orcid":false,"given":"Salman","family":"Aljarallah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Elboghdady","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynn","family":"AlHajjar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahar","family":"Shami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saeed","family":"Bohlega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9820-9579","authenticated-orcid":false,"given":"Mohammed","family":"Aljumah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,4]]},"reference":[{"issue":"11","key":"707_CR1","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1212\/WNL.0000000000000768","volume":"83","author":"P Browne","year":"2014","unstructured":"Browne P, Chandraratna D, Angood C, et al. Atlas of multiple sclerosis 2013: a growing global problem with widespread inequity. Neurology. 2014;83(11):1022\u20134.","journal-title":"Neurology"},{"issue":"3\u20134","key":"707_CR2","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1111\/jocn.16069","volume":"32","author":"KJ Dickerson","year":"2023","unstructured":"Dickerson KJ. Prognostic uncertainty in multiple sclerosis: a concept analysis. J Clin Nurs. 2023;32(3\u20134):633\u201342.","journal-title":"J Clin Nurs"},{"issue":"12","key":"707_CR3","doi-asserted-by":"publisher","first-page":"1380.e2","DOI":"10.1016\/j.amjmed.2020.05.049","volume":"133","author":"SL Hauser","year":"2020","unstructured":"Hauser SL, Cree BA. Treatment of multiple sclerosis: a review. Am J Med. 2020;133(12):1380.e2-90.e2.","journal-title":"Am J Med"},{"issue":"10076","key":"707_CR4","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1016\/S0140-6736(16)32388-1","volume":"389","author":"G Comi","year":"2017","unstructured":"Comi G, Radaelli M, Soelberg SP. Evolving concepts in the treatment of relapsing multiple sclerosis. Lancet. 2017;389(10076):1347\u201356.","journal-title":"Lancet"},{"issue":"2","key":"707_CR5","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/s40120-020-00212-5","volume":"9","author":"G Giovannoni","year":"2020","unstructured":"Giovannoni G, Lang S, Wolff R, et al. A systematic review and mixed treatment comparison of pharmaceutical interventions for multiple sclerosis. Neurol Ther. 2020;9(2):359\u201374.","journal-title":"Neurol Ther"},{"issue":"3","key":"707_CR6","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/S1474-4422(18)30443-5","volume":"18","author":"MT Wallin","year":"2019","unstructured":"Wallin MT, Culpepper WJ, Nichols E, et al. Global, regional, and national burden of multiple sclerosis 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019;18(3):269\u201385.","journal-title":"Lancet Neurol"},{"issue":"12","key":"707_CR7","doi-asserted-by":"publisher","first-page":"4312","DOI":"10.3390\/ijms21124312","volume":"21","author":"M Bross","year":"2020","unstructured":"Bross M, Hackett M, Bernitsas E. Approved and emerging disease modifying therapies on neurodegeneration in multiple sclerosis. Int J Mol Sci. 2020;21(12):4312.","journal-title":"Int J Mol Sci"},{"issue":"6","key":"707_CR8","doi-asserted-by":"publisher","first-page":"495","DOI":"10.2217\/cer-2020-0267","volume":"10","author":"IA Samjoo","year":"2021","unstructured":"Samjoo IA, Worthington E, Drudge C, et al. Efficacy classification of modern therapies in multiple sclerosis. J Comp Eff Res. 2021;10(6):495\u2013507.","journal-title":"J Comp Eff Res"},{"issue":"10076","key":"707_CR9","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1016\/S0140-6736(16)32388-1","volume":"389","author":"G Comi","year":"2017","unstructured":"Comi G, Radaelli M, S\u00f8rensen PS. Evolving concepts in the treatment of relapsing multiple sclerosis. Lancet. 2017;389(10076):1347\u201356.","journal-title":"Lancet"},{"issue":"2","key":"707_CR10","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1177\/1352458517751049","volume":"24","author":"X Montalban","year":"2018","unstructured":"Montalban X, Gold R, Thompson AJ, et al. ECTRIMS\/EAN guideline on the pharmacological treatment of people with multiple sclerosis. Mult Scler. 2018;24(2):96\u2013120.","journal-title":"Mult Scler"},{"issue":"17","key":"707_CR11","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1212\/WNL.0000000000005347","volume":"90","author":"A Rae-Grant","year":"2018","unstructured":"Rae-Grant A, Day GS, Marrie RA, et al. Practice guideline recommendations summary: disease-modifying therapies for adults with multiple sclerosis: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology. 2018;90(17):777\u201388.","journal-title":"Neurology"},{"key":"707_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.cct.2020.106009","volume":"95","author":"D Ontaneda","year":"2020","unstructured":"Ontaneda D, Tallantyre EC, Raza PC, et al. Determining the effectiveness of early intensive versus escalation approaches for the treatment of relapsing-remitting multiple sclerosis: the DELIVER-MS study protocol. Contemp Clin Trials. 2020;95:106009.","journal-title":"Contemp Clin Trials"},{"issue":"3","key":"707_CR13","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1097\/WCO.0000000000000561","volume":"31","author":"G Giovannoni","year":"2018","unstructured":"Giovannoni G. Disease-modifying treatments for early and advanced multiple sclerosis: a new treatment paradigm. Curr Opin Neurol. 2018;31(3):233\u201343.","journal-title":"Curr Opin Neurol"},{"key":"707_CR14","first-page":"1473","volume-title":"Paradigm shifts: early initiation of high-efficacy disease-modifying treatment in multiple sclerosis","author":"H-P Hartung","year":"2021","unstructured":"Hartung H-P, Meuth SG, Thompson AJ. Paradigm shifts: early initiation of high-efficacy disease-modifying treatment in multiple sclerosis. London: SAGE; 2021. p. 1473\u20136."},{"issue":"12","key":"707_CR15","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1016\/j.amjmed.2020.05.049","volume":"133","author":"SL Hauser","year":"2020","unstructured":"Hauser SL, Cree BAC. Treatment of multiple sclerosis: a review. Am J Med. 2020;133(12):1380-90.e2.","journal-title":"Am J Med"},{"key":"707_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2023.105380","volume":"82","author":"D Rog","year":"2024","unstructured":"Rog D, Brownlee W, Carod-Artal FJ, et al. Quantifying the administration and monitoring time burden of several disease-modifying therapies for relapsing multiple sclerosis in the United Kingdom: a time and motion study. Mult Scler Relat Disord. 2024;82:105380.","journal-title":"Mult Scler Relat Disord"},{"key":"707_CR17","first-page":"S5","volume":"9","author":"A Croft","year":"2016","unstructured":"Croft A, Mynors G, Roberts M, Doncaster D, Bowen A, Trust M. MS forward view: a consensus for the future of MS services. Mult Scler Trust. 2016;9:S5\u201348.","journal-title":"Mult Scler Trust"},{"key":"707_CR18","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.jns.2016.12.038","volume":"375","author":"GK Reen","year":"2017","unstructured":"Reen GK, Silber E, Langdon DW. Multiple sclerosis patients\u2019 understanding and preferences for risks and benefits of disease-modifying drugs: a systematic review. J Neurol Sci. 2017;375:107\u201322.","journal-title":"J Neurol Sci"},{"issue":"2","key":"707_CR19","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.nrl.2016.02.026","volume":"32","author":"AG Merino","year":"2017","unstructured":"Merino AG, Callizo JA, Fern\u00e1ndez OF, Pascual LL, Torres EM, Zarrantz AR-A. Consensus statement on the treatment of multiple sclerosis by the Spanish Society of Neurology in 2016. Neurologia. 2017;32(2):113\u20139.","journal-title":"Neurologia"},{"issue":"8","key":"707_CR20","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1016\/S1474-4422(18)30248-5","volume":"17","author":"G Macaron","year":"2018","unstructured":"Macaron G, Cohen JA. Integrating multiple sclerosis guidelines into practice. Lancet Neurol. 2018;17(8):658\u201360.","journal-title":"Lancet Neurol"},{"key":"707_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2019.101459","volume":"37","author":"B Yamout","year":"2020","unstructured":"Yamout B, Sahraian M, Bohlega S, et al. Consensus recommendations for the diagnosis and treatment of multiple sclerosis: 2019 revisions to the MENACTRIMS guidelines. Mult Scler Relat Disord. 2020;37:101459.","journal-title":"Mult Scler Relat Disord"},{"issue":"4","key":"707_CR22","doi-asserted-by":"publisher","first-page":"27","DOI":"10.3390\/ctn6040027","volume":"6","author":"YM Al Malik","year":"2022","unstructured":"Al Malik YM, Al Thubaiti IA, AlAmmari MA, et al. Saudi consensus recommendations on the management of multiple sclerosis: disease-modifying therapies and management of relapses. Clin Transl Neurosci. 2022;6(4):27.","journal-title":"Clin Transl Neurosci"},{"key":"707_CR23","doi-asserted-by":"publisher","unstructured":"Meshkat B, Cowman S, Gethin G, et al. Using an e-Delphi technique in achieving consensus across disciplines for developing best practice in day surgery in Ireland. J Hosp Adm. 2014;3(4). https:\/\/doi.org\/10.5430\/jha.v3n4p1.","DOI":"10.5430\/jha.v3n4p1"},{"key":"707_CR24","first-page":"7976585","volume":"2020","author":"PP Santoiemma","year":"2020","unstructured":"Santoiemma PP, Maddur H, Moore CM. A case of drug-induced liver injury secondary to natalizumab. Case Rep Hepatol. 2020;2020:7976585.","journal-title":"Case Rep Hepatol"},{"key":"707_CR25","doi-asserted-by":"publisher","unstructured":"Longbrake EE, Naismith RT, Parks BJ, Wu GF, Cross AH. Dimethyl fumarate-associated lymphopenia: risk factors and clinical significance. Mult Scler J Exp Transl Clin. 2015;1. https:\/\/doi.org\/10.1177\/2055217315596.","DOI":"10.1177\/2055217315596"},{"key":"707_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2021.103278","volume":"56","author":"C Goncuoglu","year":"2021","unstructured":"Goncuoglu C, Tuncer A, Bayraktar-Ekincioglu A, et al. Factors associated with fingolimod rebound: a single center real-life experience. Mult Scler Relat Disord. 2021;56:103278.","journal-title":"Mult Scler Relat Disord"},{"issue":"10","key":"707_CR27","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1177\/1352458519854162","volume":"26","author":"C Scarpazza","year":"2020","unstructured":"Scarpazza C, Signori A, Cosottini M, Sormani MP, Gerevini S, Capra R. Should frequent MRI monitoring be performed in natalizumab-treated MS patients? A contribution to a recent debate. Mult Scler. 2020;26(10):1227\u201336.","journal-title":"Mult Scler"},{"key":"707_CR28","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1007\/s00415-015-7986-y","volume":"263","author":"T Ziemssen","year":"2016","unstructured":"Ziemssen T, Derfuss T, de Stefano N, et al. Optimizing treatment success in multiple sclerosis. J Neurol. 2016;263:1053\u201365.","journal-title":"J Neurol"},{"issue":"9585","key":"707_CR29","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/S0140-6736(07)61194-5","volume":"370","author":"L Kappos","year":"2007","unstructured":"Kappos L, Freedman MS, Polman CH, et al. Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. Lancet. 2007;370(9585):389\u201397.","journal-title":"Lancet"},{"issue":"11","key":"707_CR30","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1016\/S1474-4422(09)70237-6","volume":"8","author":"L Kappos","year":"2009","unstructured":"Kappos L, Freedman MS, Polman CH, et al. Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase\u00a03 BENEFIT trial. Lancet Neurol. 2009;8(11):987\u201397.","journal-title":"Lancet Neurol"},{"issue":"4","key":"707_CR31","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/S1474-4422(20)30067-3","volume":"19","author":"A He","year":"2020","unstructured":"He A, Merkel B, Brown JWL, et al. Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study. Lancet Neurol. 2020;19(4):307\u201316.","journal-title":"Lancet Neurol"},{"issue":"1","key":"707_CR32","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1177\/13524585211010294","volume":"28","author":"N De Stefano","year":"2022","unstructured":"De Stefano N, Sormani MP, Giovannoni G, et al. Analysis of frequency and severity of relapses in multiple sclerosis patients treated with cladribine tablets or placebo: the CLARITY and CLARITY Extension studies. Mult Scler. 2022;28(1):111\u201320.","journal-title":"Mult Scler"},{"issue":"7","key":"707_CR33","doi-asserted-by":"publisher","first-page":"2144","DOI":"10.1111\/ene.15316","volume":"29","author":"A Signori","year":"2022","unstructured":"Signori A, Ponzano M, Alexandri N, Giovannoni G, Sormani MP. Prevalence of disability improvement in relapsing-remitting multiple sclerosis patients treated with cladribine tablets. Eur J Neurol. 2022;29(7):2144\u20137.","journal-title":"Eur J Neurol"},{"key":"707_CR34","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.828616","volume":"13","author":"C Tornatore","year":"2022","unstructured":"Tornatore C, Wiendl H, Lublin AL, et al. Vaccine response in patients with multiple sclerosis receiving teriflunomide. Front Neurol. 2022;13:828616.","journal-title":"Front Neurol"},{"key":"707_CR35","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.msard.2019.01.038","volume":"29","author":"G Comi","year":"2019","unstructured":"Comi G, Cook S, Giovannoni G, et al. Effect of cladribine tablets on lymphocyte reduction and repopulation dynamics in patients with relapsing multiple sclerosis. Mult Scler Relat Disord. 2019;29:168\u201374.","journal-title":"Mult Scler Relat Disord"},{"issue":"2","key":"707_CR36","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1177\/13524585221137502","volume":"29","author":"T Spelman","year":"2023","unstructured":"Spelman T, Ozakbas S, Alroughani R, et al. Comparative effectiveness of cladribine tablets versus other oral disease-modifying treatments for multiple sclerosis: results from MSBase registry. Mult Scler J. 2023;29(2):221\u201335.","journal-title":"Mult Scler J"},{"key":"707_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102572","volume":"46","author":"T Leist","year":"2020","unstructured":"Leist T, Cook S, Comi G, et al. Long-term safety data from the cladribine tablets clinical development program in multiple sclerosis. Mult Scler Relat Disord. 2020;46: 102572.","journal-title":"Mult Scler Relat Disord"},{"key":"707_CR38","unstructured":"EMA. Mavenclad Product Information. 2022."},{"key":"707_CR39","doi-asserted-by":"crossref","unstructured":"Rolfes L, Pfeuffer S, Hackert J, et al. Skin reactions in patients with multiple sclerosis receiving cladribine treatment. Neurol Neuroimmunol Neuroinflamm. 2021;8(3):e990.","DOI":"10.1212\/NXI.0000000000000990"},{"key":"707_CR40","doi-asserted-by":"crossref","unstructured":"Ciron J, Bourre B, Castelnovo G, et al. Holistic, long-term management of people with relapsing multiple sclerosis with cladribine tablets: expert opinion from France. Neurol Ther. 2024;13:503\u2013518.","DOI":"10.1007\/s40120-024-00589-7"},{"key":"707_CR41","volume-title":"Real-world comparative effectiveness and persistence of cladribine tablets and other oral disease-modifying treatments for multiple sclerosis from GLIMPSE: results from the MSBase Registry (P12\u20134.003)","author":"H Butzkueven","year":"2022","unstructured":"Butzkueven H, Spelman T, Ozakbas S, et al. Real-world comparative effectiveness and persistence of cladribine tablets and other oral disease-modifying treatments for multiple sclerosis from GLIMPSE: results from the MSBase Registry (P12\u20134.003). Chennai: AAN; 2022."},{"issue":"2","key":"707_CR42","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1007\/s40120-022-00339-7","volume":"11","author":"G Giovannoni","year":"2022","unstructured":"Giovannoni G, Mathews J. Cladribine tablets for relapsing-remitting multiple sclerosis: a clinician\u2019s review. Neurol Ther. 2022;11(2):571\u201395.","journal-title":"Neurol Ther"},{"issue":"12","key":"707_CR43","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1177\/1352458517727603","volume":"24","author":"G Giovannoni","year":"2018","unstructured":"Giovannoni G, Soelberg Sorensen P, Cook S, et al. Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: results from the randomized extension trial of the CLARITY study. Mult Scler. 2018;24(12):1594\u2013604.","journal-title":"Mult Scler"},{"key":"707_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2023.104735","volume":"75","author":"S Aerts","year":"2023","unstructured":"Aerts S, Khan H, Severijns D, Popescu V, Peeters LM, Van Wijmeersch B. Safety and effectiveness of cladribine tablets for multiple sclerosis: results from a single-center real-world cohort. Mult Scler Relat Disord. 2023;75:104735.","journal-title":"Mult Scler Relat Disord"},{"key":"707_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2023.578164","volume":"382","author":"I Adamec","year":"2023","unstructured":"Adamec I, Brecl Jakob G, Rajda C, et al. Cladribine tablets in people with relapsing multiple sclerosis: a real-world multicentric study from southeast European MS centers. J Neuroimmunol. 2023;382:578164.","journal-title":"J Neuroimmunol"},{"issue":"7","key":"707_CR46","doi-asserted-by":"publisher","first-page":"3553","DOI":"10.1007\/s00415-023-11700-7","volume":"270","author":"C Zanetta","year":"2023","unstructured":"Zanetta C, Rocca MA, Meani A, et al. Effectiveness and safety profile of cladribine in an Italian real-life cohort of relapsing-remitting multiple sclerosis patients: a monocentric longitudinal observational study. J Neurol. 2023;270(7):3553\u201364.","journal-title":"J Neurol"},{"issue":"3","key":"707_CR47","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1007\/s40120-022-00364-6","volume":"11","author":"M Petracca","year":"2022","unstructured":"Petracca M, Ruggieri S, Barbuti E, et al. Predictors of cladribine effectiveness and safety in multiple sclerosis: a real-world, multicenter, 2-year follow-up study. Neurol Ther. 2022;11(3):1193\u2013208.","journal-title":"Neurol Ther"},{"key":"707_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2022.103755","volume":"61","author":"I Rauma","year":"2022","unstructured":"Rauma I, Viitala M, Kuusisto H, et al. Finnish multiple sclerosis patients treated with cladribine tablets: a nationwide registry study. Mult Scler Relat Disord. 2022;61:103755.","journal-title":"Mult Scler Relat Disord"},{"key":"707_CR49","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2023.105052","volume":"79","author":"Y Song","year":"2023","unstructured":"Song Y, Wang Y, Wong SL, Yang D, Sundar M, Tundia N. Real-world treatment patterns and effectiveness of cladribine tablets in patients with relapsing forms of multiple sclerosis in the United States. Mult Scler Relat Disord. 2023;79: 105052.","journal-title":"Mult Scler Relat Disord"},{"issue":"15\u201316","key":"707_CR50","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s10354-022-00931-4","volume":"172","author":"T Moser","year":"2022","unstructured":"Moser T, Ziemssen T, Sellner J. Real-world evidence for cladribine tablets in multiple sclerosis: further insights into efficacy and safety. Wien Med Wochenschr. 2022;172(15\u201316):365\u201372.","journal-title":"Wien Med Wochenschr"},{"key":"707_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2022.104491","volume":"70","author":"PS Sorensen","year":"2023","unstructured":"Sorensen PS, Pontieri L, Joensen H, et al. Real-world experience of cladribine treatment in relapsing-remitting multiple sclerosis: a Danish nationwide study. Mult Scler Relat Disord. 2023;70:104491.","journal-title":"Mult Scler Relat Disord"},{"issue":"3","key":"707_CR52","first-page":"146","volume":"20","author":"N Ayati","year":"2021","unstructured":"Ayati N, Fleifel L, Sharifi S, Sahraian MA, Nikfar S. Cladribine tablets are a cost-effective strategy in high-disease activity relapsing multiple sclerosis patients in Iran. Curr J Neurol. 2021;20(3):146.","journal-title":"Curr J Neurol"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-024-00707-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-024-00707-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-024-00707-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,25]],"date-time":"2025-01-25T16:55:09Z","timestamp":1737824109000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-024-00707-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,4]]},"references-count":52,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["707"],"URL":"https:\/\/doi.org\/10.1007\/s40120-024-00707-5","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,4]]},"assertion":[{"value":"20 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Seraj Makkawi received an honorarium for attending the advisory board meeting on which this article is based. Also, he reports personal fees from Roche, Merck, Novartis, Sanofi Genzyme, Biogen, Janssen, Biologix, AstraZeneca, and Horizon Therapeutics outside the submitted work. Salman Aljarallah received an honorarium for attending the advisory board meeting on which this article is based. Also, he reports receiving speaker and consultation fees from Roche, Merck, Novartis, Sanofi Genzyme, Biogen, Janssen, Biologix, AstraZeneca, and Horizon Therapeutics outside the submitted work. All authors participated in the closed meeting that gave rise to this article, which was organized and supported by Merck Serono Middle East FZ-Ltd.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The study did not involve human participants, human data, or human material; thus, ethics committee approval was not required. The panelists were all authors of this paper.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}